



UNIVERSITY OF LEEDS

This is a repository copy of *Evaluation of Locoregional Recurrence Patterns Following Adjuvant (Chemo)Radiotherapy for Oral Cavity Carcinoma*.

White Rose Research Online URL for this paper:

<http://eprints.whiterose.ac.uk/156225/>

Version: Accepted Version

Article:

Waldram, R, Taylor, AE, Whittam, S et al. (10 more authors) (2020) Evaluation of Locoregional Recurrence Patterns Following Adjuvant (Chemo)Radiotherapy for Oral Cavity Carcinoma. *Clinical Oncology*, 32 (4). pp. 228-237. ISSN 0936-6555

<https://doi.org/10.1016/j.clon.2019.10.002>

© 2019 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Table 1: Patient and disease characteristics and treatment details (n=101)

	N (%)
<i>Gender</i>	
Male	58 (57.4)
Female	43 (42.6)
<i>Tobacco use at diagnosis</i>	
Ex smoker	45 (44.6)
Current smoker	36 (35.6)
No smoker	17 (16.8)
Not recorded	3 (3.0)
<i>Anatomic subsite</i>	
Floor of Mouth	17 (16.8)
Tongue	52 (51.5)
Retromolar Trigone	10 (9.9)
Mandibular alveolus	15 (14.9)
Buccal mucosa	7 (6.9)
Hard palate	0 (0)
<i>pT stage</i>	
T1	11 (10.9)
T2	40 (39.6)
T3	9 (8.9)
T4a	41 (40.6)
T4b	0 (0)
<i>pN stage</i>	
N0	37 (36.6)
N1	16 (15.8)
N2a	1 (1.0)
N2b	36 (35.6)
N2c	10 (9.9)
N3	1 (1.0)
<i>Stage group</i>	
I	6 (5.9)
II	13 (12.9)
III	13 (12.9)
IVa	69 (68.3)
<i>Histopathological differentiation</i>	
Well differentiated	4 (4.0)
Moderately differentiated	53 (52.5)
Poorly differentiated	43 (42.6)
Unclassified	1 (1.0)
<i>Margin status</i>	
Positive ($\leq 1\text{mm}$)	20 (19.8)
Close ($>1 < 5 \text{ mm}$)	44 (43.6)
Clear ($\geq 5 \text{ mm}$)	35 (34.7)
Not reported	2 (2.0)
<i>Perineural invasion</i>	
Yes	59 (58.4)
No	41 (40.6)
Not reported	1 (1.0)
<i>Lymphovascular invasion</i>	

Yes	50 (49.5)
No	48 (47.5)
Not reported	2 (2.0)
<i>Nodal involvement</i>	
Yes	73 (72.3)
No	28 (27.7)
<i>Nodal ECE (nodal involvement n=73)</i>	
Yes	30 (41.1)
No	43 (58.9)
<i>Surgery</i>	
Primary+Unilateral neck dissection	70 (69.3)
Primary+Bilateral neck dissection	27 (26.7)
Primary only	4 (4.0)
<i>Concurrent Chemotherapy</i>	
Yes	25 (24.8)
No	76 (75.2)
<i>Concurrent chemotherapy (n=25)</i>	
Cisplatin based	21 (84.0)
Carboplatin based	3 (12.0)
Cisplatin and Carboplatin Based	1 (4.0)
<i>Number of concurrent chemotherapy courses</i>	
0	77 (76.2)
1	2 (2.0)
2	22 (21.8)
<i>Radiotherapy dose</i>	
66 Gy in 33 fractions	53 (52.5)
60 Gy in 30 fractions	46 (45.5)
50 Gy in 25 fractions	1 (1.0)

Table 2: Lymph node levels irradiated with IMRT.

Nodal level (n = 101)	Ipsilateral neck radiotherapy (n=97)	Contralateral neck radiotherapy (n=53)
IA	52	30
IB	97	46
II	93	52
III	89	49
IV	90	47
V	55	21
VIIa	37	4
VIIb	28	1

Table 3: Details of analysis patients with locoregional recurrences (n=22)

Oral cavity subsite	pTNM (7 th edition)	Neck dissection	Adjuvant treatment	Failure site (related PTV)	Local versus regional recur.	Time to recur (months post RT)	%Vrec in 95% isodose	Mean dose to centroid/Gy	Recurrence classification	
Tongue	T1N1	Unilateral	RT 60Gy Bilateral Neck	Contralateral neck level III OF	R	1	0	5.7	E (extraneous, neck)	
Mandible	T4aN0	Bilateral	RT 60Gy Bilateral Neck	Buccal mucosa PTV60	L	3	36	59.1	B (peripheral, high dose)	
Tongue	T2N1	Unilateral	RT 60Gy Unilateral Neck	FOM/ventral tongue PTV60	L	6	99	62	A (central, high dose)	
Tongue	T2N0	Unilateral	RT 60Gy Unilateral Neck	Oral tongue PTV60	L	2	99	60.7	A (central, high dose)	
Tongue	T2N2c	Bilateral	RT 60Gy Bilateral Neck	FOM PTV60	L	5	98	60.2	A (central, high dose)	
Tongue	T2N2b	Unilateral	RT 60Gy Bilateral Neck	Ipsilateral level 2 LN PTV54	R	6	100	55	C (central, elective dose)	
Tongue	T2N1	Unilateral	RT 60Gy Unilateral Neck	Contralateral neck level III OF	R	4	0	9.2	E (extraneous, neck)	
Tongue	T1N0	None	RT 60Gy Unilateral Neck	Ipsilateral neck levels II-IVa and contralateral neck level 2 PTV60 (ipsilateral) and OF (contralateral)	R	28	Ipsilateral neck		A (central, high dose, ipsilateral neck) E (extraneous, contralateral neck)	
							97	60.6		
							Contralateral neck			
							0	5.4		
Tongue	T4aN2c	Bilateral	RT 60Gy Bilateral Neck	Bilateral levels Ib PTV60	R	2	Ipsilateral neck		A (central, high dose, bilateral neck)	
							100	61.5		
							Contralateral neck			
							100	60.2		
Tongue	T2N2b	Unilateral	RT 60Gy Unilateral Neck	Tongue Contralateral levels I-IVa OF	LR	9	Primary		A (central, high dose, primary) E (extraneous, contralateral neck)	
							100	60.6		
							Contralateral neck			
							0	Multifocal, centroid of each >60Gy		
Tongue	T2N0	Unilateral	RT 50Gy Unilateral Neck	OF	R	0	0	Multifocal, centroid of each <50Gy	E (extraneous, neck)	
Tongue	T2N2b	Unilateral	RT 66Gy Bilateral Neck	Ipsilateral level IVa PTV56	R	9	99	58.7	C (central, elective dose, neck)	
Mandible	T4aN0	Unilateral	RT 66Gy Unilateral Neck	Contralateral mandible OF	L	8	2.6	26.9	E (extraneous, primary)	
Tongue	T4aN0	Unilateral	RT 66Gy Bilateral Neck	Ipsilateral neck, levels II-III PTV66	R	4	100	67.8	A (central, high dose, neck)	

Buccal	T4aN2c	Bilateral	RT 66Gy Bilateral Neck	Adjacent tongue PTV66	L	5	71.8	65.3	B (peripheral high dose)
Tongue	T4aN2b	Unilateral	RT 66Gy Unilateral Neck	Ipsilateral levels Ib-II, contralateral III PTV66	R	15	96	67.2	A (central, high dose, neck)
RMT	T1N1	Unilateral	RT 66Gy Unilateral Neck	Ipsilateral level II PTV66	R	8	100	66.5	A (central, high dose, neck)
Tongue	T4aN1	Unilateral	RT 66Gy Bilateral Neck	Oral tongue PTV66	L	9	98.1	67.2	A (central, high dose, primary)
Mandible	T4aN0	Unilateral	RT 66Gy Bilateral Neck	Posterior tongue, masticator space PTV66	L	6	85.5	67.1	B (peripheral high dose, primary)
Tongue	T2N0	Unilateral	RT 66Gy Bilateral Neck	Oral tongue adjacent to flap PTV66	L	4	84.6	67.0	B (peripheral high dose, primary)
Tongue	T2N2c	Unilateral	RT 66Gy Unilateral Neck	Ipsilateral levels II/III PTV60	R	4	20.6	58.6	D (peripheral, elective dose, neck)
Buccal	T4aN1	Unilateral	RT 66Gy Bilateral Neck	Ipsilateral levels I-III PTV60	R	1	60.1	60.5	D (peripheral, elective dose, neck)

L=local; R=regional; Vrec=reccurrence volume; RMT=retromolar trigone; ECE=extracapsular extension; RT=radiotherapy;
coreg=coregistration of diagnostic recurrence imaging with planning CT; OF=out-of-field; PTV=planning target volume